United States: FDA Unveils Anticipated Draft Guidance For The Regulation Of Laboratory-Developed Tests

Last Updated: August 11 2014
Article by Paul T. Kim and Bruce Quinn


On July 31, 2014, the Food and Drug Administration (FDA) provided Congress notice of its intent to issue draft guidance providing a risk-based framework for the regulation of laboratory developed tests (LDTs) under the agency's medical device oversight authority.  The agency released two documents that provide detail on the anticipated regulatory framework for LDTs.  The first document is titled "Framework for Regulatory Oversight of Laboratory Developed Tests," and would regulate LDTs "in a manner that is consistent with FDA's current regulation of in vitro diagnostic devices."  This represents a significant departure from the agency's long standing position of "enforcement discretion" in regulating clinical diagnostic tests performed by a laboratory, and not sold as a kit.  FDA notes that it is concerned about gaps in regulation of LDTs under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), and in particular that CLIA does not assure the safety and effectiveness of LDTs, require adverse event reporting, nor require removal from the market of tests deemed unsafe.

A second document entitled "FDA Notification and Medical Device Reporting for Laboratory Developed Tests," would establish a new "notification procedure" for certain LDTs in lieu of annual registration and listing with FDA.  Under the envisioned notification procedure, LDT laboratories would initially submit on-line through the FDA website basic information about the LDT to FDA, and the agency would use the data to implement the risk-based enforcement.  Medical device reporting refers to the reporting of substantial injuries or mortality caused by device malfunction.

FDA's statutory authority to regulate LDTs has been questioned by some stakeholders, most notably in a Citizen's Petition to FDA from the American Clinical Laboratory Association (ACLA) in June, 2013.  ACLA argued that LDTs do not meet the definition of a device under the Food, Drug, and Cosmetic Act (FD&C Act).  Concurrently with the notifications, FDA released a response to ACLA's citizen petition, denying ACLA's request to refrain from regulating LDTs as devices1

In what is expected to be the first step in a lengthy process, FDA was required to notify Congress 60 days in advance of its promulgating a guidance concerning the regulation of LDTs under the Food and Drug Administration Safety and Innovation Act of 2012 (Pub. L. 112-144, Sec. 1143).  Therefore, the upcoming draft guidance will not be formally released until October 1, 2014 at the earliest, and at that time the agency will open a docket for public comment.  Importantly, FDA anticipates that enforcement of the new requirements over LDTs would be phased in following the issuance of a final guidance over several years:

  • Laboratories providing LDTs (except a few exempted categories) would comply with notification or registration/listing, and adverse event reporting, within 6 months of the issuance of the LDT final guidance.  
  • FDA would phase in its enforcement of premarket review and Quality System Regulation (QSR) —prioritizing by risk— over a period of nine years after the publication of the LDT final guidance.

The LDT notification document prioritizes the application of other regulatory requirements by risk.  Three specific high risk categories of LDTs would be subject to premarket review within 12 months of the issuance of the final LDT guidance (for existing LDTs) or immediately upon finalization of the guidance (for LDTs introduced after the final guidance is issued).  These high risk LDT categories would include tests with the same intended use as a cleared or approved companion diagnostic or an approved Class III in vitro diagnostic test.  Advisory panels would assist the FDA in classifying other LDTs into a risk based set of categories over a two-year period.  FDA refers to the resulting categorization as a "priority list."  

The new LDT notification documents address but do not answer several critical issues.  While "high-risk" tests would be first to be subject to premarket review, there is little to illuminate precisely how FDA intends to assess risk, which intended use and diagnostic claims will be permissible or feasible, or what types and amounts of evidence will be required in premarket review.  The notification documents do not reconcile medical device requirements with CLIA compliance, except in a general fashion.  Laboratory stakeholders have raised concerns that the FDA's manufacturing operations and quality control are ill-fitted to laboratory test procedures.   The notifications also do not distinguish between clinical laboratory and physician pathology laboratory tests, both of which are regulated together under CLIA, but allow exemptions for tests that require "interpretation," which may often be the case for complex genetic tests.

Dr. Jeffrey Shuren, Director of the Center for Devices and Radiological Health (CDRH), noted on a call with industry stakeholders that FDA would not require the payment of user fees for LDT laboratories.  However, it is unclear how the FDA would resource its premarket review of potentially thousands of LDTs newly subject to premarket review, or how LDTs would fare in future negotiations over medical device user fees.  Nor does the notification address whether the medical device tax or disclosure under the Physician Payment Sunshine Act will apply to LDTs registered with, versus cleared or approved, by FDA.   

Additionally, FDA released the final guidance for companion diagnostics. The draft guidance was released in July, 2011.  Since that time FDA has approved 18 companion diagnostics for use with targeted anti-cancer therapeutic agents.

Below are a timeline and a summary of the key terms and provisions.

Proposed Timeline of Implementation

Click here to see table.

Definition of an LDT

  • Definition.  The notification document defines an LDT as an in vitro diagnostic device (IVD) that is intended for clinical use and designed, manufactured and used within a single laboratory (i.e. a facility with a single CLIA certificate).  
    • Exclusions.  The definition does not include tests that are designed or manufactured completely, or partly, outside of the laboratory that offers and uses them.  Nor does the definition include direct-to-consumer (DTC) tests.  
  • Tests currently offered as LDTs.  FDA proposes to apply the same risk-based framework to tests that are currently offered as LDTs, even if they do not meet FDA's definition of an LDT. 

Risk-Based Framework

FDA will rely upon the existing medical device classification system to evaluate the risk of a category of LDTs.  The notification sets out a process to identify LDTs as Class I (low risk), Class II (moderate risk), and Class III (high risk).

  • Highest risk categories.  FDA identified three "highest risk" categories of LDTs, which would be at the top of FDA's enforcement priorities:  
    • LDTs with the same intended use as a cleared or approved companion diagnostic;
    • LDTs with the same intended use as an approved Class III medical device; and
    • Certain LDTs used to determine safety/efficacy of blood or blood products.
  • Higher concern LDTs.  FDA also identified the following categories of high risk LDTs as being of "higher concern" to the agency, immediately below the highest risk categories:
    • LDTs that act like companion diagnostics;
    • Screening LDTs for serious diseases or conditions intended for use in asymptomatic patients with no other available confirmatory diagnostic product or procedure, such as screening device for malignant cancers; and 
    • Diagnostic LDTs for certain infectious diseases with high risk intended uses.
  • Risk classification considerations. In determining the risk an LDT poses to the patient or the user, FDA would consider several factors including—
    • whether the device is intended for use in high risk disease/conditions or patient populations, 
    • whether the device is used for screening or diagnosis, 
    • the nature of the clinical decision that will be made based on the test result, 
    • whether a physician/pathologist would have other information about the patient to assist in making a clinical decision (in addition to the LDT result), 
    • alternative diagnostic and treatment options available to the patient, 
    • the potential consequences/impact of erroneous results, 
    • number and type of adverse events associated with the device, and 
    • potentially other factors. 
  • Advisory Panels. FDA would utilize advisory panels to help classify LDTs not previously classified by FDA, as appropriate. 
  • Guidance on classification.  FDA would issue a draft guidance to describe which LDTs it considers to be Class I, II, or III within 18 months of the finalization of this guidance; and a final guidance within 24 months of the finalization of the LDT guidance. 
  • Low-risk categories.  FDA identified four categories of LDTs, which pose a low risk to patients, and would therefore be subject only to notification or registration/listing, and adverse event reporting requirements:
    • LDTs used for rare diseases  (4,000 patients per year or less)
    • Traditional LDTs  (type of LDTs that were available in 1976, and LDTs used within a hospital network for its own patients)
    • LDTs for unmet needs  (as long as there is no cleared/approved alternative)
    • Class I (low-risk) LDTs  

Application of Regulatory Requirements to LDTs

The two notification documents establish a new regulatory framework for LDTs with four core requirements:  notification (or registration and listing), adverse event reporting, premarket review, and QSR requirements.  The implementation of these requirements and level of oversight is based on risk as detailed below. 

1.  Notification in lieu of registration/listing.  

  • A new notification process would be created under a separate guidance document "FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs)".  
  • Applicable to all non-exempt LDTs within 6 months of the issuance of final LDT guidance. Laboratories could choose to undergo a one-time notification process in lieu of compliance with medical device registration and listing requirements.    
    • Significant changes to an LDT would require an additional notification.  
  • Notification information should be submitted online through the FDA website.  The following data would be required for a notification:

laboratory name; test name; monthly test volume; intended use; clinical use of test; what is measured or detected; disease / condition for which the diagnostic device is indicated; patient population and whether includes pediatric; sample type; test method; and whether the test a modification of an FDA cleared/approved test, and which modifications were made.

2.  Medical device reporting.  

  • Applicable to all non-exempt LDTs within 6 months of the issuance of final guidance.  
  • LDT laboratories would be required to fulfill the MDR requirements for manufacturers (in addition to the requirements for user facilities) for all reportable events involving an LDT manufactured by the laboratory.  Unlike user facilities, manufacturers are required to—
    • report serious injuries to FDA rather than to the manufacturer;
    • fill out additional sections of MedWatch 3500A form;
    • report certain device malfunctions; and 
    • submit five day remedial action event reports to FDA. 

3.  Premarket review.  

  • FDA intends to phase in the enforcement of applicable premarket requirements over time based upon the risk associated with that device.  FDA intends to focus its efforts on the "highest risk" devices first and gradually phase in enforcement for other Class III and Class II devices over time.  
  • Phased in over 9 years: 
    • "Highest risk" Class III:  begins 12 months after issuance of final guidance.
    • Class III high risk:  begins 36 months after issuance of final guidance.
    • Class II moderate risk:  begins 5 years after issuance of final guidance. 
  • FDA believes it would not be necessary for sponsors to conduct extensive new studies to demonstrate clinical validity of analytes/markers where an LDT's analytes/markers that are measured/assessed have had their clinical validity already established in the literature, so long as the changes to technology or methodology that differ from that used in the literature to assess the analyte/marker do not affect the clinical validity of the LDT.  
  • FDA could delegate the review of 510(k) applications for most moderate risk (Class II) LDTs to accredited third-party reviewers. 
  • CDRH Director, Dr. Jeffrey Shuren, stated on a call with industry stakeholders that LDTs would not be subject to user fees. 

4.  Quality System Regulation requirements.  

  • FDA intends to continue to exercise enforcement discretion with respect to the QSR  requirements until a laboratory of a given LDT submits a premarket approval application (PMA) or FDA issues a 510(k) clearance order for the LDT.
  • This initial period of continued exercise of enforcement discretion for QSR requirements is intended to allow time for laboratories to learn about their regulatory obligations.  The agency will phase in the QSR requirements as follows:
    • "Highest risk" Class III:  Enforced once a PMA is submitted or FDA issues a clearance order.
    • Class III: QSR requirements applicable when a laboratory submits a PMA.
    • Class II: QSR requirements are applicable to a laboratory following FDA  510(k) clearance order for the LDT. 
  • FDA would consider expanding its third-party inspection program for surveillance inspections and exploring opportunities to coordinate and leverage existing programs.  
  • On a call with industry stakeholders, Dr. Shuren noted that FDA will consider relying on CLIA inspectors to inspect compliance with QSR requirements as well.   

LDTs Exempt from Regulatory Requirements

  • Categories of exempt LDTs.  FDA will continue to exercise full enforcement discretion for two categories of LDTs:
    • LDTs used solely for forensic (law enforcement) purposes; and 
    • Certain LDTs for transplantation when used in CLIA-certified, high complexity histocompatibility laboratories. 
  • Enforcement discretion.  For these categories of LDTs, there would not be any regulatory requirements enforced under the FD&C Act.


1. [See Docket No. FDA-2013-P-0667]

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions